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Abstract: 
Disease is spreading at a faster rate than ever before. Our globalized world is faced with 
the constant threat of devastating pandemics due to the increase in frequency, intensity 
and distance with which humans and goods are capable of traveling. Technology, 
information and resources, which play a crucial role in the prevention, management and 
eradication of disease, are theoretically more accessible in today’s world in terms of their 
ability to be effectively transported to the most remote regions of our planet. However, 
the international agreements and policies currently in place create barriers, preventing the 
achievement of a higher standard of global health. One such obstacle emerges as a result 
of Intellectual Property Rights (IPRs). On the one hand, these ownership rights 
acknowledge and compensate scientists for their innovations; this encourages further 
development of medication. Nevertheless, these rights make drugs unaffordable and 
inaccessible to citizens of the Global South. IPRs fail to recognize the knowledge of 
indigenous people, whose ancient herbal medicines often-times inspire the innovations. In 
doing so, IPRs breed increasing mistrust and tension on the part of those in the Global 
South towards the Global North. This article provides a case study and possible 
amendments to Intellectual Property policies with the intension of facilitating trust 
between communities, establishing a more efficient system of resource distribution, 
increasing the global standard of living through better healthcare management, and 
consequently, creating a more stable and safe world. 
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Résumé : 
La maladie se propage à un rythme plus rapide que par le passé. Notre monde globalisé 
est confronté à la menace constante de pandémies ravageuses en raison de l’augmentation 
de la fréquence, de l’intensité et de la distance que les êtres humaines et les biens sont 
capables de voyager. La technologie, l’information et les ressources, qui jouent un rôle 
critique dans la prévention, la gestion et l’éradication de la maladie sont, en théorie, plus 
accessible dans le monde d’aujourd’hui quant à leur capacité d’être transporté 
efficacement aux régions les plus éloignées de la planète. Cependant, les accords 
internationaux et les politiques en place actuellement créent des barrières qui empêchent 
la réalisation d’un niveau plus élevé de santé globale. Un tel obstacle émerge du fait de 
les Droits de Propriétés Intellectuelles (DPI). D’une part, ces droits à la propriété 
reconnaissent et récompensent les scientifiques pour les innovations ; ceci encourage le 
développement d’autres médicaments. Néanmoins, ces droits rendent les traitements 
inabordables et inaccessibles aux citoyens du Sud Global. Les DPS ne reconnaissent pas 
les savoirs des peuples autochtones, dont les médicaments anciens à bases des plantes 
sont souvent source d’inspiration pour les innovations. Ce faisant, les DPS alimente une 
méfiance et tension de part de ceux et celles dans le Sud Global envers le Nord Global. 
Cet article offre une étude de cas et propose des modifications éventuelles aux politiques 
de la Propriété Intellectuelle avec l’objectif de faciliter la confiance entre les 
communautés, d’établir un système de distribution de ressources plus efficaces, 
d’améliorer le niveau de vie mondial par une meilleure gestion des systèmes de santé et 
ainsi, de créer un monde plus stable et plus en sécurité.  
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Introduction 
Globalization is defined, for the purpose of this paper, as the increase in 
sociopolitical and economic interactions between nations. This phenomenon is facilitated by 
technological advances in communication and driven by international trade and travel. The 
rapidly evolving multidimensional relationships across political borders create 
interdependency between societies. There is some debate over the exact origin of 
globalization; some scholars believe that the process emerged in the 15th century during the 
period of colonialism. From the beginning of the European expansion, globalization has 
acted as a facilitator for the spread of disease. Anthony McMichael, an epidemiologist, 
warns that humanity is entering “the fourth great transition in human disease history;” the 
first occurred 10 000 years ago with the emergence of agricultural settlements, the second 
took place 3000 years ago “when the classical civilization of Europe and Asia met” and the 
third when Europeans came into contact with First Nations Peoples.1 Nunn & Qian (2010) 
introduce a concept called the “Columbian Exchange,” in which the Old World gained new 
crops and innovations, and the New World suffered a drastic reduction in population.2 The 
indigenous peoples of the Americas were vulnerable to the diseases brought to them by 
explorers. Outbreaks of smallpox and yellow fever during the colonial period wiped out 
entire tribes. Today, diseases are spreading faster than ever before; mass-migration into 
mega-cities in which overcrowding and poverty create an ideal environment for bacterial 
growth is a common occurrence. A recent example is the outbreak of SARS in 2003, which 
was initiated by a Chinese doctor, infected with the viral respiratory disease, who stayed 
overnight in a Hong Kong hotel. Despite his limited contact with other individuals during 
                                                          
1 Yvonne Baskin, “Winners and losers in a changing world,” BioScience, no. 48 (1999): 788-792. 
2 Nathan Nunn  and Nancy Qian, “The Columbian Exchange: A History of Disease, Food and Ideas,” Journal 
of Economic Perspectives, no. 2 (2010): 163-188. 
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his stay, according to Murray (2006), 12 other guests on the same floor were eventually 
diagnosed with SARS.3  
Two monumental actors in global health are the World Bank and the World Trade 
Organization (WTO). The latter administers the agreement on Trade-Related Aspects of 
Intellectual Property Rights (IPRs), also known as TRIPs, which provides an international 
standard for the regulation and protection of intellectual property. IRPs are beneficial in the 
sense that they provide incentives for the development of new drugs and medicines. IPRs 
allow for the innovator to experience positive reinforcement; rewarding scientists for their 
work has the beneficial psychological effect of motivating further research. However, IPRs 
come at a cost; they breed mistrust on the part of the Global South towards the Global 
North, creating political and social tension. The world has reached a critical point in terms 
of healthcare; diseases are spreading faster than ever due to globalization. The need to treat 
and eradicate diseases implicates many other factors outside the realm of science. This 
paper outlines the good intentions of Intellectual Property Rights and their grave 
consequences; a case study of the outbreak of AIDS in Brazil is presented along with 
possible amendments to IPRs.  Economic and political barriers are considered when 
evaluating IPRs and proposing possible solutions to this global crisis. 
 
Benefits and Consequences of IPRs 
IPRs grant the exclusive use of an intellectual creation; these rights are granted by 
the state. IPRs include patents, copyright and various other examples of academic property 
related to innovations. Once an idea is established as a property, it cannot be copied or 
utilized without the authorization of the owner. From a financial aspect, IPRs are beneficial 
                                                          
3 Megan Murray, “The epidemiology of SARS”, in SARS in China: prelude to pandemic?  Stanford: Stanford 
University Press (2006): 17-30. 
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to the patent owner. These exclusive exploitation rights of the product enable the possessor 
of the patent to earn back the monetary funds invested into the research and production of 
the drug, often times enabling them to make a profit. Without intellectual property, 
individuals would be reluctant to share their ideas and to pursue them because it would be 
financially unrewarding and discouraging to not be given ownership and recognition for 
their innovation. IPRs acknowledges scientists for their innovations, this is a form of 
positive reinforcement which increases the likelihood of further research. For this reason, it 
is clear that, from the perspective of the Global North, IPRs are essential for scientific 
advancement.  
However, it is also evident that the existence of such rights makes accessibility and 
affordability of medical treatment and drugs in developing countries very difficult. There is 
a discrepancy in the way different groups of people are affected by the same policies. The 
situation is unsettling; while IPRs regulate the distribution of medication for the purpose of 
offering the innovator a chance to receive compensation and praise for their significant 
contribution to the health sector, in many developing countries, the majority do not even 
have access to the benefits of these innovations, which are quite common in other areas of 
the world.  
There is a strong need to accommodate both the needs of patients and patent-
holders, while maintaining the priority of ameliorating access to the bare minimal standard 
of health care. The process of placing a new product on the market is both financially 
burdensome and time-consuming. It remains necessary to compensate scientists for their 
contribution, in the form of countless hours of research and experimentation, to humanity. 
Without recognition and reward they will be less inclined to pursue a career in research. It is 
important to note that many nations face catastrophic health problems which must be 
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addressed sooner rather than later. This life threatening need has caused some countries to 
reject IPRs and instead grant compulsory licensing. Compulsory licensing is government 
approval to produce a patented good without the agreement of the patent-holder. There is a 
great injustice for the millions of people who die from diseases for which treatments exist.4 
Case Study: Brazil and the HIV Outbreak 
Firstly, let’s consider a case study of the consequences of IPRs and the controversial 
decision a nation had to make in order to find an effective solution for their citizens. The 
interdependence between global health and international organizations is demonstrated in 
the case of the Human Immunodeficiency Virus (HIV). HIV has a rather lengthy latency 
period in which the infected individual may not even be aware that they have the disease. 
This often leads to the unintentional spread of the virus. In Botswana and Swaziland, it is 
approximated that more than 40% of adults are HIV positive.4 
In 1996, David Ho was a leading scientist in the creation of a drug that could 
suppress the level of the virus in the bloodstream. This mixture of antiretroviral medications 
was not a cure, but rather a treatment that had to be maintained permanently or else the 
virus would re-emerge. The treatment cost was around $10 000 to $15 000 annually, a fee 
perhaps manageable solely by citizens of the Global North.  
Brazil experienced an outbreak of AIDS in the late 1980s, with infection rates 
increasing drastically in an exponential manner. It was estimated that nations in the Global 
South would have to pay pharmaceutical companies approximately $10 000 a year to 
produce the required medication, while it would cost only $150 to $300 a year to produce 
the same drugs in a laboratory on their own soil.5 In an attempt to make antiretroviral drugs 
universally available, Brazil created an internationally controversial program which would 
                                                          
4 Shawn C. Smallman & Kimberley Brown, Introduction to International & Global Studies, (Chapel Hill: 
University of North Carolina Press, 2011), 242 
5 Ibid., 248 
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provide medication for free beginning in 1996.6 During the course of the next four years, 
Brazil was able to reduce the cost of AIDS medication by 72.5% through the local 
manufacturing of two-thirds of the drugs in the treatment.7  
Brazil’s decision to grant compulsory licensing and manufacture generic AIDS 
drugs created a large dispute. The United States, prompted by the lobbying of 
pharmaceutical companies, accused the Brazilian government of violating trade law under 
the system of the TRIPs regime for their disfavor of imported goods.8 They threatened the 
state with the possibility of sanctions and even the closure of numerous pharmaceutical 
companies since they believed that the policy “would discourage the research needed to 
produce new HIV/AIDS medication”.9 The argument for developing countries was 
supported by many non-profit organizations who emphasized that often-times, medication is 
developed with the use of public funds and thus the public should have access to it and a say 
in its global distribution. In response to the accusations, a Brazilian advertisement surfaced 
claiming that “local manufacturing of many of the drugs used in the anti-AIDS cocktail is 
not a declaration of war against the drug industry. It is simply a fight for life”.10 Eventually 
the conflict was abruptly stopped when the United Nations declared access to treatment for 
AIDS as a human right and the WTO stated at their 2001 conference that TRIPs does not 
and should not prevent member states from taking drastic measures to protect public health. 
This resolution prompted many developing countries to seek the expansion of access to 
medications for their citizens and demonstrated that “global health is not only shaped by 
                                                          
6 Smallman  and  Brown, Introduction to International & Global Studies, 248 
7 Alan Berkman et. al, “A Critical Analysis of the Brazilian Response to HIV/AIDS: Lessons Learned for 
Controlling and Mitigating the Epidemic in Developing Countries,” American Journal of Public Health, no. 7 
(2005): 162-172. 
8 Smallman  and  Brown, Introduction to International & Global Studies, 248 
9 Ibid., 248 
10 Roy Wadia, “Brazil’s AIDS Policy Earns Global Plaudits,” Cable News Network, August 16, 2001, 
http://edition.cnn.com/2001/WORLD/americas/08/14/brazil.AIDS/. 
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microbes but also by international organizations”.11 “Globalization is a two-edged sword”12; 
its dual nature cuts both opponents. The spread of disease affects citizens in all areas of the 
world; viruses which are maintained due to lack of treatment accessibility can be 
transported to the Global North with ease, through commercial travel and trade. 
Globalization enables the spread of disease and barriers for health care at the same time as it 
sets the foundation for international organization and a network of funding for countries 
facing disasters. 
Compensation for Indigenous Knowledge 
Another issue with global health that arises in the debate over the existence of IPRs 
is compensation of knowledge. The majority of medications are derived from plants.13 
Usually, the discovery of the medicinal functions of plants are rooted in the knowledge of 
Native Peoples. For example, quinine, used in the treatment of malaria, was invented by 
Peruvians.14 It is evident that indigenous peoples had a complex understanding of chemical 
interactions from their skill in combining various plants to create medications. Thus, the 
discovery of new drugs is not a one-way exchange of knowledge, technology and resources, 
trickling from the Global North to the Global South; traditional medicine is finding its way 
from developing nations to scientists in developed nations.  
Unfortunately, indigenous people are not compensated for their knowledge. Rural 
communities fear that if they share their knowledge, pharmaceutical companies who 
produce the medication will patent the recipe. Once they lay claim to the idea, IPRs will 
prevent farmers from continuing local production and sale of the medication. In a sense, 
even when the idea originates in developing nations, IPRs which are meant to protect the 
                                                          
11 Smallman  and  Brown, Introduction to International & Global Studies, 249 
12 Ibid., 252 
13 Ibid., 249 
14 Wade Davis, One River: Explorations and Discoveries in the Amazon Rain Forest, (New York: Touchstone, 
1997), quoted in Smallman and  Brown, Introduction to International & Global Studies, 249. 
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ownership of those ideas fail to compensate and acknowledge the citizens of the Global 
South. In essence, IPRs appear to apply only when it is beneficial for the rich nations.  
Some efforts have been made to establish policies to ensure the compensation of 
indigenous for their knowledge.15 This topic was discussed, for example, at the 1992 United 
Nations Conference on the Environment and Development. However, powerful actors such 
as the USA, objected to the idea thus preventing any agreement or policy from being 
established. Without copyright laws protecting the ownership of valuable knowledge, 
pharmaceutical companies are able to produce synthetic versions of drugs. One such case is 
that of Artemisia annua, more commonly known as Sweet Wormwood, which has 
therapeutic effects against some forms of malaria.16 The increased need for this Chinese 
herbal medicine gave rise to the potential for developing an industry since large amounts of 
the plant were required to create the drug. “The discovery of artemisinin is a triumph that 
has had both medical and social benefits”.17 This was an opportunity for farmers to improve 
their business and for the nation to contribute to the global market. The success of the herb 
to treat malaria prompted companies to try to create a synthetic version of the plant. If a 
company were to succeed in creating a synthetic chemical that could mimic the effects of 
the plant, they would be able to patent the medication and thus farmers would no longer 
have legal access to sell the herbal remedy. There would also no longer be demand for 
production of the plant; this would have devastating costs for the farmers and communities 
which depend on the industry this plant has created. According to an article in the 
International Weekly Journal of Science by Mark Peplow, Sanofi, a Paris-based 
pharmaceutical company, succeeded in converting fermenting yeast to produce artemisinin-
                                                          
15 Smallman and Brown, Introduction to International & Global Studies, 252 
16 R. Thom, “Artemisia Annua: A Cure for Malaria”, Unpublished student manuscript (2006), quoted in 
Smallman and Brown, Introduction to International & Global Studies, 251 
17 Smallman and Brown, Introduction to International & Global Studies, 251 
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based combination therapies.18 The discovery threatened the producers of the natural 
chemical. However, due to economic barriers, the synthetic substance hasn’t achieved the 
anticipated level of distribution; while sweet wormwood based medicine sells for $250 per 
kilogram, the company’s no-profit margin is $350-$400 per kilogram. As of now, there is 
no synthetic substance that overtakes the affordability of the natural product. If this were to 
change in the future, IPRs would be at the center of yet another debate. Once again, it is 
evident that IPRs fail to protect the rights of those in the Global South. 
 
Decision Making Policy 
 When looking at decision making policy in the international community, two models 
provide acceptable frameworks under which to evaluate health issues and identify 
resolutions. According to Waltner-Toews & Lang (2000), “the role of knowledge and 
science in both [competing] models is critical” however the two models vary greatly in 
approach and application.19 The first is referred to as the Input-Output model and is 
described as a linear system where science and capital are the two variables inputted and 
under which increased production with proper distribution results in improved health.  In 
this first model, the main goal of science is to increase production and efficiency.20 This is 
the dominant model used in international policy evaluation. The second model, currently 
emerging, is known as the complex model. This model considers health to be a roof held up 
by pillars such as accessibility, availability and affordability, which shelter factors that 
range from the economic to ecological state of society and include elements such as culture, 
                                                          
18 Mark Peplow, “Synthetic biology’s first malaria drug meets market resistance” Nature News (2016) 
http://www.nature.com/news/synthetic-biology-s-first-malaria-drug-meets-market-resistance-1.19426. 
19 David Waltner-Toews and Tim Lang, “A new conceptual base for food and agricultural policy: the 
emerging model of links between agriculture, food, health, environment and society,” Global Change & 
Human Health, no. 2 (200): 116-128. 
20 Ibid. 
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water and energy. In the complex model “health relies on a diversity of factors”.21 There is 
a growing recognition that the relationships between these factors are more interdependent 
than previously thought. While consideration of the stability of all these diverse variables is 
essential in maintaining the sustainability of global health, it is possible that in cases which 
require immediate solutions, the Input-Output Model is far more suitable. The limitation of 
the linear system is that it assumes that productivity is the sole goal. Increasing the supply, 
however, only provides a temporary solution since the issues of diseases implicate a 
complex system of policies, agreements, cultural and religious controversy and other 
elements which need to be considered. It appears that while the complex model is an 
essential tool to understand our interconnected world, without immediate results, our 
society faces the risk of a rapid reduction in population. When an outbreak occurs, nations 
seek a quick remedy and in many cases find difficulty with the decreased accessibility and 
availability of treatment resulting from IPRs. In cases such as the aforementioned Brazilian 
HIV outbreak, nations chose to, in a sense, violate these laws in order to ensure that public 
health was prioritized. This is done through the use of compulsory licensing which a nation 
grants, enabling a laboratory to produce cheaper generic forms. While it is acknowledged 
that their actions are condemned by some advocates of IPRs and may be seen as 
discouraging to the scientific community, patents would be useless if there were no patients 
left to benefit from the medication. 
 
Solutions 
Perhaps the most effective model to use in policy making is a combination of the 
two, where patent-holders are respected so that further innovations are encouraged and their 
                                                          
21 David Waltner-Toews and Tim Lang, “A new conceptual base for food and agricultural policy: the 
emerging model of links between agriculture, food, health, environment and society” 
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hard work is compensated and, at the same time, the needs of the patients are met with equal 
attention, placing both production and accessibility at the forefront of the system.  
It is evident that IPRs have a large impact on the cost and accessibility of medicines, 
resulting in a growing focus on methods in which to lower pricing for developing countries, 
with some nations opting to use compulsory licensing. International organizations, such as 
the World Health Organization and Centers for Disease Control and Prevention were 
established to monitor and treat outbreaks. In striving for eradication of diseases and the 
preservation of life, mechanisms like relaxed patent requirements, voluntary licensing, bulk 
purchasing and corporate donations have all proven to be effective methods in which to 
bring about affordability and availability of drugs and treatments without violating TRIPs. It 
is in the best interest of states in the Global North to provide aid to nations in the Global 
South in order to maintain world-wide health standards. Developed countries could, in times 
of crisis, allocate some financial support for developing nations as well as exercise some 
leniency to infringements of IPRs in certain extenuating circumstances.  
It is also the moral duty of the patent-holder to participate in increasing accessibility 
to drugs and treatments. Their involvement is essential because of the power they possess 
over their products. Voluntary licensing is an agreement between a state and the patent-
holder to reproduce the product at a more affordable price; this compromise ensures that 
neither side loses. Since negotiations are at the discretion of the patent-holder, the benefits 
of the agreement largely vary depending on the terms. Providing the owner with control 
over the distribution and cost of the pharmaceutical product can go both ways. On the one 
hand, this method ensures that incentives to develop new innovations are still in place since 
patent-holders still have rights to their properties and in negotiations many nations are able 
to more easily access new drugs. However, in other instances, agreement terms can provide 
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minimal aid, leaving nations still unable to treat the disease. This is seen when patent-
holders act in self-interest, such as for the sole purpose of placing their product on the 
market. This usually results in prices which remain affordable only to some, most 
commonly citizens of the Global North. Nevertheless, this mechanism allows for the 
potential for some drugs to become accessible in the Global South.  
Another possible solution is for an international organization such as the WHO or 
WTO to monitor the distribution and cost of medicines to ensure accessibility in developing 
nations. Taxation systems could be established which allocate some of the money paid by 
developed nations for drugs to be used in the creation of funds which would be used to 
reduce the price of these same products for developing countries. Bulk purchasing may 
provide communities with a more affordable cost when they opt for a large amount of 
drugs. Governments could also provide incentives for private corporations to help fund 
developing nations’ purchase of medication. A good way to do this is by providing tax 
reductions or reimbursements for donating. 
 
Conclusion 
Health is a global issue because of the ability for diseases to cross political and 
geographical borders; pandemics do not discriminate and, as a result, all global citizens are 
at risk. The consequences, but nevertheless necessity, of IPRs are evident when it comes to 
medical treatments and global health. Globalization enables the creation of International 
Organizations, such as the World Health Organization which fights disease outbreak, and 
the United Nations which fights for the improvement of health standards.22 It also creates a 
forum for wealthy nations to provide funds when they are urgently needed by the Global 
                                                          
22 Smallman and Brown, Introduction to International & Global Studies, 252 
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South. Globalization facilitates the exchange of information, technology and resources. At 
the same time, this phenomenon enables the spread of disease through the increased 
transportation of people and goods, and occasionally, allows nations and institutes to 
prevent the production of generic drugs. IPRs create a barrier which prevents the 
accessibility of medicines in developing countries, at times forcing nations to take drastic 
measures. The reaction of the Brazilian government to the outbreak of AIDS, although 
controversial, is admirable due to their intention to save thousands of patients and to sustain 
the welfare of the state. The decision to grant compulsory licensing was the only solution in 
their case, but it works solely as a temporary method with consequences of sanctions due to 
the discrimination of imported goods and the disregard for the rights of the patent-holders. 
It is essential for the international society to seek a long-term beneficial mechanism to meet 
the needs of both the patent-holder and the patients.  
Two methods which were mentioned in the paper could potentially ameliorate the 
relationship between the patent-holders and the Global South, as well as solve the problem 
of accessibility and affordability. One mechanism which should be implemented more and 
further encouraged is voluntary licensing which enables agreements between the patient-
holder and the state at the discretion of the owner. This method has been shown to reduce 
the cost of drugs and treatments in many cases. A second mechanism suggested was the 
establishment of a taxation system in which a portion of the cost paid for medicines by the 
Global North is used to reduce the cost of those same products on the markets of the Global 
South. Both methods require cooperation and compromise for the well-being of the global 
public. International organizations and multinational corporations should work with both 
developed and developing nations to accommodate the needs of all humans. The bare 
minimum healthcare which allows an individual to survive curable diseases and maintain a 
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comfortable lifestyle should be recognized by all states and groups as a human right that 
should be protected. It is only in a system which acknowledges the importance of 
immediate action and increased productivity, as well as maintains consideration for 
economic, ecological and cultural factors, that a desired standard of global health can be 
obtained. This can be done without the abolishment of IPRs which are so essential to the 
development of new innovations, but rather with mechanisms that cushion the consequences 
of this system and provide the environment for a sustainable and thriving world.   
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